CN108191966A - 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 - Google Patents
一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 Download PDFInfo
- Publication number
- CN108191966A CN108191966A CN201810024865.XA CN201810024865A CN108191966A CN 108191966 A CN108191966 A CN 108191966A CN 201810024865 A CN201810024865 A CN 201810024865A CN 108191966 A CN108191966 A CN 108191966A
- Authority
- CN
- China
- Prior art keywords
- residue
- polypeptide
- iron
- blood
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 165
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 114
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 113
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 44
- 150000003254 radicals Chemical class 0.000 title claims abstract description 29
- 230000008499 blood brain barrier function Effects 0.000 title claims abstract description 16
- 210000001218 blood-brain barrier Anatomy 0.000 title claims abstract description 16
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims abstract description 23
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 14
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 9
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical group OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 7
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 235000015177 dried meat Nutrition 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 abstract description 37
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract description 15
- 230000006378 damage Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 206010012289 Dementia Diseases 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 102000005962 receptors Human genes 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 238000010586 diagram Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 230000008557 oxygen metabolism Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 7
- 206010039966 Senile dementia Diseases 0.000 description 6
- 101710153593 Albumin A Proteins 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000002380 cytological effect Effects 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000018152 Cerebral disease Diseases 0.000 description 2
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 2
- -1 Fe2+ ions Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004987 nonapoptotic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000533950 Leucojum Species 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000441 X-ray spectroscopy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810024865.XA CN108191966B (zh) | 2018-01-11 | 2018-01-11 | 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810024865.XA CN108191966B (zh) | 2018-01-11 | 2018-01-11 | 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108191966A true CN108191966A (zh) | 2018-06-22 |
CN108191966B CN108191966B (zh) | 2020-10-27 |
Family
ID=62588960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810024865.XA Active CN108191966B (zh) | 2018-01-11 | 2018-01-11 | 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108191966B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021441A1 (en) * | 2004-08-25 | 2006-03-02 | Cellzome Ag | Biphenyl-carboxylic acids and derivatives thereof and their use in therapy |
CN102123726A (zh) * | 2008-06-12 | 2011-07-13 | 阿费里斯股份公司 | 用于治疗与帕金森氏病有关的症状的化合物 |
CN102863525A (zh) * | 2011-07-04 | 2013-01-09 | 武汉大学 | 一种重组人apoE拟肽及制备方法和应用 |
CN102984938A (zh) * | 2010-05-13 | 2013-03-20 | 肯塔基大学研究基金会 | 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法 |
CA3005212A1 (en) * | 2015-11-11 | 2017-05-18 | Warner Babcock Institute for Green Chemistry | Benzofuran derivatives for the treatment of cns and other disorders |
CN107022019A (zh) * | 2016-11-24 | 2017-08-08 | 台州学院 | 一种用于脑内降铁除自由基的多肽、制备方法与应用 |
-
2018
- 2018-01-11 CN CN201810024865.XA patent/CN108191966B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006021441A1 (en) * | 2004-08-25 | 2006-03-02 | Cellzome Ag | Biphenyl-carboxylic acids and derivatives thereof and their use in therapy |
CN102123726A (zh) * | 2008-06-12 | 2011-07-13 | 阿费里斯股份公司 | 用于治疗与帕金森氏病有关的症状的化合物 |
CN102984938A (zh) * | 2010-05-13 | 2013-03-20 | 肯塔基大学研究基金会 | 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法 |
CN102863525A (zh) * | 2011-07-04 | 2013-01-09 | 武汉大学 | 一种重组人apoE拟肽及制备方法和应用 |
CA3005212A1 (en) * | 2015-11-11 | 2017-05-18 | Warner Babcock Institute for Green Chemistry | Benzofuran derivatives for the treatment of cns and other disorders |
CN107022019A (zh) * | 2016-11-24 | 2017-08-08 | 台州学院 | 一种用于脑内降铁除自由基的多肽、制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
C. BRIANI, S. RUGGERO: "Combined analysis of", 《JOURNAL OF NEURAL TRANSMISSION》 * |
Also Published As
Publication number | Publication date |
---|---|
CN108191966B (zh) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fasano et al. | The extraordinary ligand binding properties of human serum albumin | |
Wang et al. | The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia‐ischemia as potently as erythropoietin | |
Motterlini et al. | Heme oxygenase-1–derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo | |
Sun et al. | Binding of bismuth to serum proteins: implication for targets of Bi (III) in blood plasma | |
Sharma et al. | New perspectives of nanoneuroprotection, nanoneuropharmacology and nanoneurotoxicity: modulatory role of amino acid neurotransmitters, stress, trauma, and co-morbidity factors in nanomedicine | |
Tsan et al. | Mechanism of gallium-67 accumulation in tumors | |
Olivo et al. | Mapping ALA-induced PPIX fluorescence in normal brain and brain tumour using confocal fluorescence microscopy | |
Gray et al. | Delta-sleep-inducing peptide: solution conformational studies of a membrane-permeable peptide | |
US20090043073A1 (en) | Alpha-fetoprotein peptides and uses for imaging | |
US11274125B2 (en) | Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease | |
US10428127B2 (en) | Cyclic, amyloid beta-binding peptides and the use thereof | |
Sanders | Light chain-mediated tubulopathies | |
CN108191966A (zh) | 一种含导肽可穿越血脑屏障螯合脑内铁降自由基的多肽 | |
Zou et al. | Linking the low‐density lipoprotein receptor‐binding segment enables the therapeutic 5‐YHEDA peptide to cross the blood‐brain barrier and scavenge excess iron and radicals in the brain of senescent mice | |
Chua-anusorn et al. | The effect of histological processing on the form of iron in iron-loaded human tissues | |
Zou et al. | Using the synthesized peptide HAYED (5) to protect the brain against iron catalyzed radical attack in a naturally senescence Kunming mouse model | |
Di Natale et al. | Affinity, speciation, and molecular features of copper (II) complexes with a prion tetraoctarepeat domain in aqueous solution: Insights into old and new results | |
JP2006515156A (ja) | 新規なアルブミン | |
US20100113366A1 (en) | Use of proline-rich peptide derived from hypothalamus for the manufacture of a medicament for the treatment and/or prophylaxis of cattle leucosis | |
Okubo et al. | Precision engineered peptide targeting leukocyte extracellular traps mitigate acute kidney injury in Crush syndrome | |
Al-Achi et al. | Human insulin binding to erythrocyte-membrane | |
CN112759656A (zh) | 一种用于解除脑内神经元细胞铁胁迫的多肽 | |
Şincai et al. | The effects of magnetic fluids on blood parameters in dogs | |
Yang et al. | α-Synuclein pathology from the body to the brain: so many seeds so close to the central soil | |
Dorn et al. | Immunoreactive glucagon in neurons of various parts of the human brain. Demonstration by immunofluorescence technique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200922 Address after: 541001 No. two, 109 North Road, Guilin, the Guangxi Zhuang Autonomous Region Applicant after: GUILIN MEDICAL University Address before: 317700 No. 1139, Shifu Road, Jiaojiang District, Taizhou, Zhejiang. Applicant before: TAIZHOU University |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240126 Address after: Room 1506-3, Pujiang Building, No. 26 Pujiang Road, Gulou District, Nanjing City, Jiangsu Province, 210036 Patentee after: Nanjing Ruijian Fukang Information Technology Co.,Ltd. Country or region after: China Address before: 541001 No. two, 109 North Road, Guilin, the Guangxi Zhuang Autonomous Region Patentee before: GUILIN MEDICAL University Country or region before: China |
|
TR01 | Transfer of patent right |